Pressure
BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly
enabling, pressure-based technology and products to the worldwide life sciences
and other industries, today announced that its patented pressure cycling
technology (“PCT”) platform was featured as an integral part of an innovative
new workflow for the analysis of proteins from cancer biopsy samples. The
workflow was presented during a plenary session at the Annual Meeting of the
International Gynecologic Cancer Society (“IGCS”) on September 21, 2019 in Rio
de Janeiro, Brazil. According to the update, Dr. Thomas Conrads, a nationally
acclaimed protein chemist and the senior director of Women’s Health Research at
the Inova Women’s Hospital, and his colleagues developed the novel workflow.
“We are very pleased to have been invited to present the results of our work in
gynecologic cancer research in a plenary session at this important
international meeting,” Dr. Conrads commented in the news release. “The novel
workflow developed by our group integrates and operationalizes state-of-the art
techniques: laser microdissection (“LMD”), pressure cycling technology (“PCT”),
and mass spectrometry (“MS”) to improve our understanding of the complex tissue
microenvironment and, in this case, to enable identification of biomarkers
associated with women’s cancers. We believe that the insights we gain from
applying this novel workflow will result in significant improvements in the
clinical management of gynecologic cancer.”
To view the full press release, visit http://ibn.fm/uFgJ8
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired, patented technology from BaroFold,
Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract
services sector, and (2) the use of its recently-patented, scalable,
high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i)
create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and
water) and to (ii) prepare higher quality, homogenized, extended shelf-life or
room temperature stable low-acid liquid foods that cannot be effectively
preserved using existing non-thermal technologies. For more information, visit
the company’s website at www.PressureBiosciences.com
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
